Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry.

Kosyakovsky J, Witthuhn BA, Svitak AL, Frey WH 2nd, Hanson LR, Fine JM.

ACS Chem Neurosci. 2019 Oct 15. doi: 10.1021/acschemneuro.9b00436. [Epub ahead of print]

PMID:
31573798
2.

Correction to: The AGING Initiative experience: a call for sustained support for team science networks.

Garg T, Anzuoni K, Landyn V, Hajduk A, Waring S, Hanson LR, Whitson HE.

Health Res Policy Syst. 2019 May 20;17(1):52. doi: 10.1186/s12961-019-0429-y.

3.

Feasibility Trial of a 10-Week Adaptive.

Hall SF, Wiering BA, Erickson LO, Hanson LR.

Pain Manag Nurs. 2019 Aug;20(4):316-322. doi: 10.1016/j.pmn.2019.01.001. Epub 2019 May 15.

PMID:
31103513
4.

Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats.

Rautiola D, Maglalang PD, Cheryala N, Nelson KM, Georg GI, Fine JM, Svitak AL, Faltesek KA, Hanson LR, Mishra U, Coles LD, Cloyd JC, Siegel RA.

J Pharmacol Exp Ther. 2019 Sep;370(3):796-805. doi: 10.1124/jpet.118.255943. Epub 2019 Mar 5.

PMID:
30837282
5.

Solitary bone plasmacytoma compression injury disguised as back pain: a case report.

Jackson SD, Wiering BA, Herrmann AA, Hinz MA, Hanson LR.

Spinal Cord Ser Cases. 2019 Feb 11;5:16. doi: 10.1038/s41394-019-0161-4. eCollection 2019.

PMID:
30774986
6.

From A to D: A Unique Case Report of Recovery After Longitudinal Myelitis Related to Lupus.

Jackson SD, Wiering BA, Bentley IA, Herrmann AA, Hanson LR.

Am J Phys Med Rehabil. 2019 Oct;98(10):e119-e122. doi: 10.1097/PHM.0000000000001117.

PMID:
30557157
7.

Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain.

Dewji NN, Azar MR, Hanson LR, Frey Ii WH, Morimoto BH, Johnson D.

J Alzheimers Dis Rep. 2018 Oct 24;2(1):169-179. doi: 10.3233/ADR-180078.

8.

Rescue therapies for seizure emergencies: New modes of administration.

Maglalang PD, Rautiola D, Siegel RA, Fine JM, Hanson LR, Coles LD, Cloyd JC.

Epilepsia. 2018 Oct;59 Suppl 2:207-215. doi: 10.1111/epi.14479. Epub 2018 Aug 29.

9.

Screening Positive for Cognitive Impairment: Impact on Healthcare Utilization and Provider Action in Primary and Specialty Care Practices.

Rosenbloom M, Barclay TR, Borson S, Werner AM, Erickson LO, Crow JM, Lakshminarayan K, Stuck LH, Hanson LR.

J Gen Intern Med. 2018 Oct;33(10):1746-1751. doi: 10.1007/s11606-018-4606-4. Epub 2018 Aug 10.

10.

The AGING Initiative experience: a call for sustained support for team science networks.

Garg T, Anzuoni K, Landyn V, Hajduk A, Waring S, Hanson LR, Whitson HE.

Health Res Policy Syst. 2018 May 18;16(1):41. doi: 10.1186/s12961-018-0324-y. Erratum in: Health Res Policy Syst. 2019 May 20;17(1):52.

11.

Oxytocin enhances observational fear in mice.

Pisansky MT, Hanson LR, Gottesman II, Gewirtz JC.

Nat Commun. 2017 Dec 13;8(1):2102. doi: 10.1038/s41467-017-02279-5.

12.

Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.

Fine JM, Forsberg AC, Stroebel BM, Faltesek KA, Verden DR, Hamel KA, Raney EB, Crow JM, Haase LR, Knutzen KE, Kaczmarczek KD, Frey WH, Hanson LR.

J Neurol Sci. 2017 Sep 15;380:164-171. doi: 10.1016/j.jns.2017.07.028. Epub 2017 Jul 21.

PMID:
28870559
13.

Research Priorities to Advance the Health and Health Care of Older Adults with Multiple Chronic Conditions.

Tisminetzky M, Bayliss EA, Magaziner JS, Allore HG, Anzuoni K, Boyd CM, Gill TM, Go AS, Greenspan SL, Hanson LR, Hornbrook MC, Kitzman DW, Larson EB, Naylor MD, Shirley BE, Tai-Seale M, Teri L, Tinetti ME, Whitson HE, Gurwitz JH.

J Am Geriatr Soc. 2017 Jul;65(7):1549-1553. doi: 10.1111/jgs.14943. Epub 2017 May 26.

14.

Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.

Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, Hanson LR, Kozarsky KF, Orchard PJ, Frey WH 2nd, Low WC, McIvor RS.

Hum Gene Ther. 2017 Jul;28(7):576-587. doi: 10.1089/hum.2017.187. Epub 2017 Apr 20.

15.

Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model.

Khan RS, Dine K, Bauman B, Lorentsen M, Lin L, Brown H, Hanson LR, Svitak AL, Wessel H, Brown L, Shindler KS.

Sci Rep. 2017 Jan 31;7:41768. doi: 10.1038/srep41768.

16.

Food consumption and activity levels increase in rats following intranasal Hypocretin-1.

Dhuria SV, Fine JM, Bingham D, Svitak AL, Burns RB, Baillargeon AM, Panter SS, Kazi AN, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2016 Aug 3;627:155-9. doi: 10.1016/j.neulet.2016.05.053. Epub 2016 Jun 2.

PMID:
27264485
17.

Routine cognitive screening in a neurology practice: Effect on physician behavior.

Rosenbloom M, Borson S, Barclay T, Hanson LR, Werner A, Stuck L, McCarten J.

Neurol Clin Pract. 2016 Feb;6(1):16-21.

18.

Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.

Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, Conway PM, Stroebel BM, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2015 Jan 1;584:362-7. doi: 10.1016/j.neulet.2014.11.013. Epub 2014 Nov 13.

PMID:
25445365
19.

A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR.

CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.

PMID:
25373630
20.

Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.

Fine JM, Forsberg AC, Renner DB, Faltesek KA, Mohan KG, Wong JC, Arneson LC, Crow JM, Frey WH 2nd, Hanson LR.

Brain Res. 2014 Jul 29;1574:96-104. doi: 10.1016/j.brainres.2014.05.048. Epub 2014 Jun 10.

PMID:
24928620
21.

Intranasal administration of CNS therapeutics to awake mice.

Hanson LR, Fine JM, Svitak AL, Faltesek KA.

J Vis Exp. 2013 Apr 8;(74). doi: 10.3791/4440.

22.

Intranasal delivery of insulin via the olfactory nerve pathway.

Renner DB, Svitak AL, Gallus NJ, Ericson ME, Frey WH 2nd, Hanson LR.

J Pharm Pharmacol. 2012 Dec;64(12):1709-14. doi: 10.1111/j.2042-7158.2012.01555.x. Epub 2012 Jul 4.

PMID:
23146033
23.

Mindfulness-based stress reduction for family caregivers: a randomized controlled trial.

Whitebird RR, Kreitzer M, Crain AL, Lewis BA, Hanson LR, Enstad CJ.

Gerontologist. 2013 Aug;53(4):676-86. doi: 10.1093/geront/gns126. Epub 2012 Oct 15.

24.

Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice.

Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd.

Drug Deliv Transl Res. 2012 Jun;2(3):160-8. doi: 10.1007/s13346-011-0050-2.

PMID:
25786865
25.

Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.

Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR.

Exp Brain Res. 2012 Jun;219(3):381-90. doi: 10.1007/s00221-012-3101-0. Epub 2012 May 1.

PMID:
22547371
26.

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

Wolf DA, Hanson LR, Aronovich EL, Nan Z, Low WC, Frey WH 2nd, McIvor RS.

Mol Genet Metab. 2012 May;106(1):131-4. doi: 10.1016/j.ymgme.2012.02.006. Epub 2012 Feb 10.

PMID:
22420937
27.

Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

Renner DB, Frey WH 2nd, Hanson LR.

Neurosci Lett. 2012 Apr 4;513(2):193-7. doi: 10.1016/j.neulet.2012.02.037. Epub 2012 Feb 22.

PMID:
22387067
28.

Intranasal delivery of growth differentiation factor 5 to the central nervous system.

Hanson LR, Fine JM, Hoekman JD, Nguyen TM, Burns RB, Martinez PM, Pohl J, Frey WH 2nd.

Drug Deliv. 2012 Apr;19(3):149-54. doi: 10.3109/10717544.2012.657720. Epub 2012 Feb 22.

PMID:
22353012
29.

Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states.

Martinez JA, Kasamatsu M, Rosales-Hernandez A, Hanson LR, Frey WH, Toth CC.

Mol Pain. 2012 Jan 11;8:3. doi: 10.1186/1744-8069-8-3. Retraction in: Mol Pain. 2014;10:20.

30.

Intranasal treatment of neurodegenerative diseases and stroke.

Gomez D, Martinez JA, Hanson LR, Frey WH 2nd, Toth CC.

Front Biosci (Schol Ed). 2012 Jan 1;4:74-89. Review.

PMID:
22202044
31.

Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.

Liu Z, Li Y, Zhang L, Xin H, Cui Y, Hanson LR, Frey WH 2nd, Chopp M.

Neurobiol Dis. 2012 Feb;45(2):804-9. doi: 10.1016/j.nbd.2011.11.004. Epub 2011 Nov 15.

32.

Recruiting and retaining family caregivers to a randomized controlled trial on mindfulness-based stress reduction.

Whitebird RR, Kreitzer MJ, Lewis BA, Hanson LR, Crain AL, Enstad CJ, Mehta A.

Contemp Clin Trials. 2011 Sep;32(5):654-61. doi: 10.1016/j.cct.2011.05.002. Epub 2011 May 12.

33.

Motor end plate innervation loss in diabetes and the role of insulin.

Francis GJ, Martinez JA, Liu WQ, Zochodne DW, Hanson LR, Frey WH 2nd, Toth C.

J Neuropathol Exp Neurol. 2011 May;70(5):323-39. doi: 10.1097/NEN.0b013e318215669a.

PMID:
21487310
34.

Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice.

Hanson LR, Hafez D, Svitak AL, Burns RB, Li X, Frey WH 2nd, Marr RA.

J Mol Neurosci. 2011 Mar;43(3):424-7. doi: 10.1007/s12031-010-9460-8. Epub 2010 Oct 13.

PMID:
20941644
35.

Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Johnson NJ, Hanson LR, Frey WH.

Mol Pharm. 2010 Jun 7;7(3):884-93. doi: 10.1021/mp100029t.

36.

Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease.

Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):195-201. doi: 10.1089/rej.2009.0944.

PMID:
20370487
37.

Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharm Sci. 2010 Apr;99(4):1654-73. doi: 10.1002/jps.21924. Review.

PMID:
19877171
38.

Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS.

Alcalá-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey WH 2nd, McLoon LK.

J Drug Target. 2010 Apr;18(3):179-90. doi: 10.3109/10611860903318134.

39.

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.

Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS.

J Pharmacol Exp Ther. 2009 Sep;330(3):679-86. doi: 10.1124/jpet.108.149807. Epub 2009 Jun 9.

40.

Intranasal insulin ameliorates experimental diabetic neuropathy.

Francis G, Martinez J, Liu W, Nguyen T, Ayer A, Fine J, Zochodne D, Hanson LR, Frey WH 2nd, Toth C.

Diabetes. 2009 Apr;58(4):934-45. doi: 10.2337/db08-1287. Epub 2009 Jan 9. Retraction in: Diabetes. 2014 May;63(5):1817.

41.
42.

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharm Sci. 2009 Jul;98(7):2501-15. doi: 10.1002/jps.21604.

PMID:
19025760
43.

Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C.

Brain. 2008 Dec;131(Pt 12):3311-34. doi: 10.1093/brain/awn288. Epub 2008 Nov 16. Retraction in: Brain. 2014 Jun;137(Pt 6):e283.

PMID:
19015157
44.

Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis.

Martinez JA, Francis GJ, Liu WQ, Pradzinsky N, Fine J, Wilson M, Hanson LR, Frey WH 2nd, Zochodne D, Gordon T, Toth C.

Neuroscience. 2008 Dec 10;157(4):908-25. doi: 10.1016/j.neuroscience.2008.08.073. Epub 2008 Oct 2. Retraction in: Neuroscience. 2014 Sep 5;275:549.

PMID:
18951954
45.

Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.

Dhuria SV, Hanson LR, Frey WH 2nd.

J Pharmacol Exp Ther. 2009 Jan;328(1):312-20. doi: 10.1124/jpet.108.145565. Epub 2008 Oct 22.

PMID:
18945930
46.

Delivery of interferon-beta to the monkey nervous system following intranasal administration.

Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd.

Neuroscience. 2008 Mar 27;152(3):785-97. doi: 10.1016/j.neuroscience.2008.01.013. Epub 2008 Jan 16.

PMID:
18304744
47.

Intranasal tat alters gene expression in the mouse brain.

Pulliam L, Sun B, Rempel H, Martinez PM, Hoekman JD, Rao RJ, Frey WH 2nd, Hanson LR.

J Neuroimmune Pharmacol. 2007 Mar;2(1):87-92. Epub 2007 Jan 9.

PMID:
18040830
48.

Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

Hanson LR, Frey WH 2nd.

J Neuroimmune Pharmacol. 2007 Mar;2(1):81-6. Epub 2006 Sep 15. Review.

PMID:
18040829
49.

The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats.

Liu XF, Fawcett JR, Hanson LR, Frey WH 2nd.

J Stroke Cerebrovasc Dis. 2004 Jan-Feb;13(1):16-23.

PMID:
17903945
50.

Supplemental Content

Loading ...
Support Center